Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 3/20 | 0.47 |
| ▸ | SRC | P12931 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18370671 | 0.87 | ABL1 (0.57) | ABL1SRC | |
| SCHEMBL833789 | 0.83 | KDM4E (0.48) | ABL1SRCL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL5218804 | 0.82 | KDM4E (0.57) | ABL1SRCL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL24201478 | 0.81 | KDM4E (0.49) | ABL1SRCL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL1313379 | 0.80 | KDM4E (0.48) | ABL1SRCL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL14802296 | 0.80 | ALOX15 (0.59) | ABL1SRCL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL5218433 | 0.80 | KDM4E (0.51) | ABL1SRCL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL297938 | 0.79 | DAO (0.41) | ABL1SRCKDM4EALDH1A1HPGD | |
| SCHEMBL3099393 | 0.79 | RAB9A (0.60) | ABL1SRCL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL30147636 | 0.79 | PKM (0.48) | ABL1SRCKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025067168-A1 | AZA FUSED RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州爱科百发生物医药技术有限公司 | 2025-04-03 | — | — | WO | disclosed |
| US-20240336629-A1 | Tricyclic Derivatives Useful As PARP7 Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
| CN-117430606-A | Sulfonamide PARP7 inhibitors | 山东轩竹医药科技有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-117396485-A | PARP7 inhibitors | 轩竹生物科技股份有限公司 | 2024-01-12 | — | — | CN | disclosed |
| EP-4291560-A1 | TRICYCLIC DERIVATIVES USEFUL AS PARP7 INHIBITORS | Jacobio Pharmaceuticals Co., Ltd. (CN) | 2023-12-20 | — | — | EP | disclosed |
| CN-116848114-A | Tricyclic derivatives useful as PARP7 inhibitors | 北京加科思新药研发有限公司 | 2023-10-03 | — | — | CN | disclosed |
| WO-2022170974-A9 | TRICYCLIC DERIVATIVES USEFUL AS PARP7 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-03-30 | — | — | WO | disclosed |
| WO-2022247839-A1 | PARP7 INHIBITOR | 山东轩竹医药科技有限公司 | 2022-12-01 | — | — | WO | disclosed |
| WO-2022170974-A1 | TRICYCLIC DERIVATIVES USEFUL AS PARP7 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-08-18 | — | — | WO | disclosed |
| WO-2022170974-A1 | TRICYCLIC DERIVATIVES USEFUL AS PARP7 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-08-18 | — | — | WO | disclosed |
| US-8143248-B2 | Tricyclic N-heteroaryl-carboxamide derivatives containing a benzimidazole unit, method for preparing same and their therapeutic use | SANOFI-AVENTIS (FR) | 2012-03-27 | — | — | US | disclosed |
| US-8044066-B2 | Derivatives of pyrrolopyridine-2-carboxamides, preparation thereof and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2011-10-25 | — | — | US | disclosed |
| US-20110009400-A1 | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
| US-20110009364-A1 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
| US-20100249183-A1 | THERAPEUTIC USE OF N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | US | disclosed |
| US-7763636-B2 | N-(arylalkyl)-1H-pyrrolopyridine-2-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-07-27 | — | — | US | disclosed |
| US-20100173929-A1 | Tricyclic N-heteroaryl-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | disclosed |
| US-20090298865-A1 | Derivatives of pyrrolopyridine-2-carboxamides, preparation thereof and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2009-12-03 | — | — | US | disclosed |
| US-20090042873-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-12 | — | — | US | disclosed |
| US-20080125459-A1 | N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125459-A1 | N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | CYP3A5, ZYX, ZDHHC2 | ABL1 15/4885SRC 2072/4885L3MBTL1 4735/4885 |
| US-20090042873-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | CYP3A5, CYP2C8, PAICS | ABL1 106/4885SRC 3071/4885L3MBTL1 4095/4885 |
| US-20110009400-A1 | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | XDH, NQO2, HDAC1 | ABL1 166/4885SRC 1766/4885L3MBTL1 4803/4885 |
| US-20100173929-A1 | Tricyclic N-heteroaryl-carboxamide derivatives, preparation and therapeutic use thereof | ZDHHC7, CNR2, HDAC3 | ABL1 429/4885SRC 3053/4885L3MBTL1 2291/4885 |
| US-20110009364-A1 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | ZYX, XDH, ZFX | ABL1 568/4885SRC 1219/4885L3MBTL1 4592/4885 |
| US-20090298865-A1 | Derivatives of pyrrolopyridine-2-carboxamides, preparation thereof and therapeutic application thereof | PYCR1, ATP5PD, NQO2 | ABL1 24/4885SRC 2606/4885L3MBTL1 4861/4885 |
| US-20240336629-A1 | Tricyclic Derivatives Useful As PARP7 Inhibitors | PARP1, PARP2, PARP11 | ABL1 1564/4885SRC 3394/4885L3MBTL1 3068/4885 |
| US-20100249183-A1 | THERAPEUTIC USE OF N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES | ZDHHC2, ZYX, GLS2 | ABL1 19/4885SRC 1896/4885L3MBTL1 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.